
Oncolytics Biotech ( ($ONCY) ) has provided an announcement. On November 19, 2026, the Company held its virtual annual meeting, with holders of 65,061,822 shares, representing 49.61% of outstanding votes,
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| ONCY | Oncolytics Biotech | 0.35 | -0.55 | -61.00% |
| Name | Price | % Change | |
|---|---|---|---|
| $0.35 | -61.00% |

Oncolytics Biotech ( ($ONCY) ) has provided an announcement. On November 19, 2026, the Company held its virtual annual meeting, with holders of 65,061,822 shares, representing 49.61% of outstanding votes,

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Oncolytics Biotech today and set a price target of $5.00. Patrick Trucchio gave his Buy rating based on several factors,

Oncolytics Biotech (ONCY) has disclosed a new risk, in the Share Price & Shareholder Rights category. The analyst notes that Oncolytics Biotech faces a significant listing risk after Nasdaq notified

Oncolytics Biotech ( ($ONCY) ) has issued an update. On November 11, 2026, Oncolytics Biotech announced it had entered a clinical supply agreement with Coherus Oncology to evaluate pelareorep with

Oncolytics Biotech, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on the stock and has a

Oncolytics (ONCY) announced that it has entered into a clinical supply agreement with Coherus Oncology (CHRS) to evaluate Oncolytics’ investigational oncolytic virus immunotherapy, pelareorep, in combination with Coherus’ next-generation PD-1

Oncolytics Biotech ( ($ONCY) ) has provided an update. Oncolytics announced translational data from a Phase 1b/2 study in heavily pretreated patients with relapsed or refractory multiple myeloma. Single-cell sequencing

Oncolytics (ONCY) Biotech announced translational data in heavily pretreated relapsed/refractory multiple myeloma patients, which will be presented at the 68th American Society of Hematology Annual Meeting and Exposition. Highlights from

The latest update is out from Oncolytics Biotech ( ($ONCY) ). On November 4, 2026, Oncolytics Biotech announced translational data from an ongoing study of pelareorep in second-line or later

Oncolytics (ONCY) Biotech announced new translational data from an ongoing study showing pelareorep’s ability to increase human papillomavirus-16-specific T cell clones and tumor-infiltrating lymphocyte clones in second-line or later squamous
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Feb 26, 2027TBA | $53.18M | $-0.06 | $0.00 | -0.08 | -1.38 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.